

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/581,345 09/		9/27/2000	Ira H. Pastan	15280-339PC	2468
7	590	08/01/2003			
Laurence J H			EXAMINER		
Townsend & T 8th Floor	ownsend	& Crew	HELMS, LARRY RONALD		
Two Embarcadero Center San Francisco, CA 94111-3834				ART UNIT	PAPER NUMBER
,				1642	າ /
			DATE MAILED: 08/01/2003	21	

Please find below and/or attached an Office communication concerning this application or proceeding.

₹ .	•	Application N .	Applicant(s)				
		09/581,345	PASTAN ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Larry R. Helms	1642				
	- The MAILING DATE of this communication ap		the c rrespondence address				
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)⊠	Responsive to communication(s) filed on <u>04</u>	<u>June 2003</u> .					
2a)⊠	This action is FINAL . 2b) T	his action is non-final.					
3)□ Disposition	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)🖂	Claim(s) <u>113-121 and 123-165</u> is/are pending	g in the application.					
4	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)⊠							
7) Claim(s) is/are objected to.							
8)□	Claim(s) are subject to restriction and/	or election requirement.	•				
Application	Application Papers						
9) The specification is objected to by the Examiner.							
10)⊠ The drawing(s) filed on <u>04 June 2003</u> is/are: a)□ accepted or b)⊠ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) $igtimes$ The proposed drawing correction filed on <u>6/4/03</u> is: a) $igcap$ approved b) $igtimes$ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)[a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority document	its have been received.					
	2. Certified copies of the priority documen	its have been received in App	lication No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14)⊠ A	cknowledgment is made of a claim for domes	tic priority under 35 U.S.C. §	119(e) (to a provisional application).				
a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment	(s)						
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	mmary (PTO-413) Paper No(s) prmal Patent Application (PTO-152)				
U.S. Patent and Tra PTO-326 (Rev		Action Summary	Part of Paper No. 21				

Art Unit: 1642

DETAILED ACTION

- Claims 33-96 have been canceled.
 Claims 113, 135, 140 were amended.
- 2. Claims 113-121, 123-165 are under examination.
- 3. The text of those sections of Title 35 U.S.C. code not included in this office action can be found in a prior Office Action

Drawings

4. The proposed drawing correction filed on 6/4/03 has been disapproved because it is not in the form of a pen-and-ink sketch showing changes in red ink or with the changes otherwise highlighted. See MPEP § 608.02(v).

Sequence Requirements

5. This application is still not in sequence compliance because amended figure 1 was not added to the specification because it did not contain a red marked up copy of the amended Figure 1. Supplying a marked up copy of Figure 1 would obviate the sequence requirements because Figure 1 would be the same as SEQ ID NO:5.

Art Unit: 1642

Rejections Withdrawn

6. The rejection of claims 113-121, 123-144, under 35 U.S.C. 112, first paragraph, because the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims is withdrawn in view of the amendments to the claims.

Response to Arguments

7. The rejection of claims 113-121, 123-165 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention is maintained.

The response filed 6/4/03 has been carefully considured but is deemed not to be persuasive. The response states that the attached printout from an E-mail from Dr. Chowdhury overcomes the rejection. In response to this argument, the E-mail is acknowledged but is not in declaration form. The incorporation of essential material in the specification by reference to a GenBank is improper. Applicant is required to amend the disclosure to include the material incorporated by reference. The amendment must be accompanied by an affidavit or declaration executed by the applicant, or a practitioner representing the applicant, stating that the amendatory material consists of the same material incorporated by reference in the referencing application. See *In re Hawkins*, 486 F.2d 569, 179 USPQ 157 (CCPA 1973); *In re Hawkins*, 486 F.2d 579,

Art Unit: 1642

179 USPQ 163 (CCPA 1973); and *In re Hawkins*, 486 F.2d 577, 179 USPQ 167 (CCPA 1973).

8. The rejection of claim 120 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention is maintained.

The response filed 6/4/03 has been carefully considured but is deemed not to be persuasive. The response states that the incorporation of the dsFv fragments of the 252 application is limited to a generic statement and does not refer only to dsFv fragments in general but to the entire application and the entirety of the specification of the '252 application including the designation of particular residues that can be mutated to cysteines has always legally been part of the specification. In response to this argument, the part of the specification that references the '252 application is headed "antibodies" and is directed to examples of immunoglobulins and to genetically engineered forms and includes dsFv fragments. The passage does not incorporate the residues that would be altered to form the dsFv. There is nothing in the passage that limits one to only altering the recited residues in claim 120 to cysteines.

Applicant is required to provide specific support for the claimed limitation in the specification as originally filed or remove it from the claim.

Art Unit: 1642

Conclusion

- 9. No claims are allowed.
- 10. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Larry R. Helms, Ph.D, whose telephone number is (703) 306-5879. The examiner can normally be reached on Monday through Friday from 7:00 am to 4:30 pm, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Art Unit: 1642

12. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 308-4242.

Respectfully,

Larry R. Helms Ph.D.

703-306-5879

LARRY R. HELMS, PH.D PRIMARY EXAMINER